Information Provided By: 
Fly News Breaks for July 31, 2015
MRK, NLNK
Jul 31, 2015 | 13:19 EDT
After NewLink Genetics (NLNK) and partner Merck (MRK) announced interim results from a Phase III trial of NewLink's Ebola vaccine, Mizuho said the results were promising and that though the FDA may show some caution, the firm does not expect that to impede development. The firm does not expect NewLink to profit from the vaccine’s use in outbreak areas, but said strategic stockpiling contracts could offer upside. Mizuho keeps a Buy rating and $62 price target on NewLink shares.
News For NLNK;MRK From the Last 2 Days
There are no results for your query NLNK;MRK
